Juventas Therapeutics, Inc. Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
1/3/2011 7:47:25 AM
CLEVELAND, Jan. 3, 2011 /PRNewswire/ -- Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI). JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1), which has been shown in several pre-clinical studies to promote tissue repair through activation of natural stem-cell repair pathways, promotion of new blood vessel formation and prevention of on-going cell death. The new trial builds on the JVS-100 cardiovascular program that includes a U.S. Phase I heart failure (HF) clinical trial for which the Company recently completed enrollment of 17 patients.
"Juventas is excited to extend its clinical pipeline to include treatment of patients with CLI," stated Rahul Aras, Ph.D., President & CEO for Juventas Therapeutics. "With our heart failure and critical limb ischemia programs moving into mid-stage clinical trials, the Company is focused on leveraging its regenerative medicine platform to address a range of cardiovascular indications with the goal of providing novel therapies to patients with limited options."
The randomized, placebo-controlled study will evaluate the efficacy and safety of JVS-100 in 48 patients (36 JVS-100 treated; 12 placebo) with Rutherford Class IV or V CLI. The clinical trial will measure several efficacy endpoints including time to amputation, transcutaneous oximetry (TcPO2), Ankle-Brachial Index (ABI) and ulcer closure.
"Critical limb ischemia is a devastating disease for which there is currently no FDA-approved drug for treatment," said Douglas Losordo, M.D., Principal Investigator for the trial and Director of the Feinberg Cardiovascular Research Institute at the Northwestern University Feinberg School of Medicine. "Novel regenerative therapies, such as JVS-100, have the potential to restore blood flow and improve outcomes for these patients."
There are approximately 3 million U.S. citizens with critical limb ischemia. The hospital treatment costs for these patients exceed $10 billion with average in-patient charges surpassing those for stroke or heart attack. Within a year of CLI diagnosis, up to 50% of patients will undergo an amputation and 25% will die.
The Juventas therapeutic platform is based on discoveries made nearly a decade ago by Marc Penn, M.D., Ph.D., Director of the Bakken Heart-Brain Institute at the Cleveland Clinic and Juventas' Chief Medical Officer. Dr. Penn demonstrated that SDF-1 is a strong chemo-attractant for hematopoietic stem cells (HSCs), with the potential to promote cardiac repair when delivered to the heart hours to months following a heart attack. These findings were published in 2003 in The Lancet and have now been validated by several independent laboratories. The SDF-1 repair pathway is conserved in most end organ systems, including the heart, peripheral vasculature, kidney, skin, liver and eye.
"Our work on SDF-1 originates from the hypothesis that we all have a natural stem cell based repair process that attempts to repair organs following injury," states Dr. Penn. "We believed that if we could identify the molecular factors that activate this pathway, they could be delivered at a time post-injury to promote tissue preservation. SDF-1 has proven to be a key player in driving repair and we are excited to see our findings translating to the clinic with the potential to help patients".
About Juventas Therapeutics
Juventas Therapeutics, headquartered in Cleveland, OH, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat lifethreatening diseases. Founded in 2007 with an exclusive license from the Cleveland Clinic, Juventas has secured more than $10 million in venture capital and grant funding to transition its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.
The company's lead product, JVS-100 encodes Stromalcell Derived Factor 1 (SDF1). SDF-1 promotes tissue repair through recruitment of endogenous stem cells to the damaged organ, promotion of new blood vessel formation and prevention of ongoing cell death. The SDF-1 repair pathway is well-conserved in a broad range of end organ systems, including the heart, vasculature, dermis, kidney, and eye. JVS-100 is currently being clinically evaluated for treatment of heart failure and late stage peripheral vascular disease and has been shown to protect and repair tissue following organdamage in a broad range of preclinical disease models.
Juventas Therapeutics, Inc.
Rahul Aras, Ph.D.
SOURCE Juventas Therapeutics, Inc.